Novo Nordisk A/S (NVO)
- Previous Close
124.53 - Open
123.30 - Bid --
- Ask --
- Day's Range
122.51 - 124.10 - 52 Week Range
75.56 - 138.28 - Volume
2,837,617 - Avg. Volume
5,059,227 - Market Cap (intraday)
550.363B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
46.32 - EPS (TTM)
2.65 - Earnings Date --
- Forward Dividend & Yield 1.37 (1.12%)
- Ex-Dividend Date Mar 22, 2024
- 1y Target Est
143.37
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
www.novonordisk.comRecent News: NVO
Performance Overview: NVO
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NVO
Valuation Measures
Market Cap
550.36B
Enterprise Value
549.90B
Trailing P/E
46.31
Forward P/E
37.59
PEG Ratio (5yr expected)
2.39
Price/Sales (ttm)
16.69
Price/Book (mrq)
36.11
Enterprise Value/Revenue
2.37
Enterprise Value/EBITDA
4.80
Financial Highlights
Profitability and Income Statement
Profit Margin
36.03%
Return on Assets (ttm)
23.39%
Return on Equity (ttm)
88.07%
Revenue (ttm)
232.26B
Net Income Avi to Common (ttm)
83.68B
Diluted EPS (ttm)
2.65
Balance Sheet and Cash Flow
Total Cash (mrq)
30.23B
Total Debt/Equity (mrq)
25.34%
Levered Free Cash Flow (ttm)
54.1B
Research Analysis: NVO
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: NVO
Analyst Report: Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingBearishPrice TargetWeekly Stock List
Our list this week shines a light on international stocks. We sorted our database for large-cap international stocks valued above $50 billion and with a High or Medium-High Argus rating for Financial Strength. We then sorted further, looking for stocks in the group that are furthest from their 52-week high, suggesting value. Timing matters, of course, and stocks have been on a tear lately. We ran the same list a month ago and note some shifting today. Roche Holding was on our initial list, but we have since downgraded it to a HOLD. Novo Nordisk has had tremendous attention from investors, but was not on our previous list as it was hitting new highs -- and has fallen from those highs in the past few weeks. Here is our current list of Argus large-cap BUY-rated international stocks that seem to offer value.
Technical Assessment: Neutral in the Intermediate-Term
We don't want to get too excited about the Russell 2000 (IWM $208), but the index is pushing up against key chart resistance once again. IWM is poking its head above prior highs seen in 12/2023, 3/2022, and the January 2022 breakdown level near $207. Since that breakdown over two years ago, IWM has traded in a volatile range, with the bottom down at $160.
Weekly Stock List
We see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.